Effect of N-acetylcysteine as adjunct therapy versus placebo on clinical outcomes and serum levels of oxidative stress biomarkers in patients with systolic heart failure

Effect of N-acetylcysteine as adjunct therapy versus placebo on clinical outcomes and serum levels of oxidative stress biomarkers in patients with systolic heart failure: a double blind clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N333

Enrollment

Registered

2020-01-11

Start date

2020-01-21

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systolic heart failure. Systolic (congestive) heart failure

Interventions

Intervention 1: Intervention group: Routine treatment plus adjunct therapy with N-acetylcysteine tablet 600 mg (manufactured by Hakim Pharmaceutical Company) every 12 hours for 3 months. Intervention

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age of 18 to 80 years, Systolic heart failure, Constant drug treatment for heart failure for at least 2 months, Stable clinical and hemodynamic status,

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding, Concomitant chronic liver, kidney or respiratory diseases, History of myocardial infarction

Design outcomes

Primary

Measure	Time frame
Left and right ventricular ejection fraction. Timepoint: Bfore and 3 months after the intervention. Method of measurement: By echocardiography.;Left and right ventricular Tei-index. Timepoint: Bfore and 3 months after the intervention. Method of measurement: By echocardiography.;Left and right ventricular strain. Timepoint: Bfore and 3 months after the intervention. Method of measurement: By echocardiography.;Activity of catalase enzyme. Timepoint: Before and 3 months after the intervention. Method of measurement: By in vitro serum analysis.;Activity of superoxide dismutase enzyme. Timepoint: Before and 3 months after the intervention. Method of measurement: By in vitro serum analysis.;Activity of peroxidase enzyme. Timepoint: Before and 3 months after the intervention. Method of measurement: By in vitro serum analysis.;Activity of malondialdehyde enzyme. Timepoint: Before and 3 months after the intervention. Method of measurement: By in vitro serum analysis.;Activity of total antioxidant capacity. Timepoint: Before and 3 months after the intervention. Method of measurement: By in vitro serum analysis.	—

Measure

Time frame

Left and right ventricular ejection fraction. Timepoint: Bfore and 3 months after the intervention. Method of measurement: By echocardiography.;Left and right ventricular Tei-index. Timepoint: Bfore and 3 months after the intervention. Method of measurement: By echocardiography.;Left and right ventricular strain. Timepoint: Bfore and 3 months after the intervention. Method of measurement: By echocardiography.;Activity of catalase enzyme. Timepoint: Before and 3 months after the intervention. Method of measurement: By in vitro serum analysis.;Activity of superoxide dismutase enzyme. Timepoint: Before and 3 months after the intervention. Method of measurement: By in vitro serum analysis.;Activity of peroxidase enzyme. Timepoint: Before and 3 months after the intervention. Method of measurement: By in vitro serum analysis.;Activity of malondialdehyde enzyme. Timepoint: Before and 3 months after the intervention. Method of measurement: By in vitro serum analysis.;Activity of total antioxidant capacity. Timepoint: Before and 3 months after the intervention. Method of measurement: By in vitro serum analysis.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Maryam Mehrpooya

Hamedan University of Medical Sciences

M_mehrpooya2003@yahoo.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 20, 2026